☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
horizon
Horizon Published (MIRROR) Trial Results of Krystexxa (pegloticase) + Methotrexate for Uncontrolled Gout in ACR Open Rheumatology
July 7, 2023
Horizon Presents New P-IV Trial Results of Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease at ENDO 2023
June 20, 2023
Horizon Entered into a Multi-Year Scientific Collaboration with Johns Hopkins University School of Medicine to Advance Research in...
November 17, 2022
Horizon Reports the Completion of Patients Enrollment of Tepezza (teprotumumab-trbw) in the P-III (OPTIC-J) Trial for the Treatmen...
November 17, 2022
Horizon Reports the Completion of Patient Enrollment of Tepezza (teprotumumab-trbw) in P-IV Trial for Thyroid Eye Disease
September 30, 2022
Horizon Published P-IV (MIRROR) Trial Results of Krystexxa (pegloticase) for the Treatment of Uncontrolled Gout in Arthritis & Rhe...
September 15, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.